The Anti-Inflammatory Effects of Argatroban Can Be Differentiated from Other Direct Thrombin Inhibitors: Experimental and Clinical Observations

ABSTRACT

The direct thrombin inhibitors (DTIs) argatroban, lepirudin, and bivalirudin are used for the management of thrombosis in patients with heparin-induced thrombocytopenia (HIT). Based on the structure of argatroban, there may be additional pharmacological effects beyond thrombin inhibition, such as vasomodulation, anti-inflammatory, and cellular modulatory effects. Plasma samples collected from HIT patients treated with argatroban (n = 20), lepirudin (n = 15), or bivalirudin (n = 15) were profiled for markers of inflammation. Circulating levels of myeloperoxidase (MPO), CD-40 ligand (CD40L), and functional microparticles (thrombin generating) were higher in HIT patients versus controls. MPO, CD40L, and microparticles significantly decreased with argatroban (p < 0.05) but were unaffected with lepirudin and bivalirudin treatment. Circulating nitric oxide (NO) levels were upregulated in HIT patients, but no significant changes were observed with any DTI treatment. However, NO levels measured in platelets were increased with argatroban treatment, suggesting that NO may be involved in the suppression of platelet activation in HIT. These observations demonstrate a robust inflammatory state associated with HIT, and biological effects of argatroban beyond thrombin inhibition that are not characteristic of lepirudin or bivalirudin.

KEYWORDS

Direct thrombin inhibitors - heparin-induced thrombocytopenia - inflammation - argatroban - lepirudin - bivalirudin

REFERENCES

• 1 Fenton J W. Regulation of thrombin generation and functions.  Semin Thromb Hemost. 1988;  14(3) 234-240
• 2 Di Nisio M, Middeldorp S, Buller H R. Direct thrombin inhibitors.  N Engl J Med. 2005;  353(10) 1028-1040
• 3 Saiah E, Soares C. Small molecule coagulation cascade inhibitors in the clinic.  Curr Top Med Chem. 2005;  5(16) 1677-1695
• 4 Lubenow N, Eichler P, Lietz T, Farner B, Greinacher A. Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies.  Blood. 2004;  104(10) 3072-3077
• 5 Lewis B E, Wallis D E, Berkowitz S D et al.. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia.  Circulation. 2001;  103(14) 1838-1843
• 6 Lewis B E, Wallis D E, Leya F, Hursting M J, Kelton JG;. Argatroban-915 Investigators . Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.  Arch Intern Med. 2003;  163(15) 1849-1856
• 7 Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia.  Circulation. 2003;  108(17) 2062-2065
• 8 Eriksson B I, Wille-Jorgensen P, Kalebo P et al.. A comparison of recombinant hirudin with low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.  N Engl J Med. 1997;  337(19) 1329-1335
• 9 Eriksson B I, Ekman S, Lindbratt S et al.. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.  J Bone Joint Surg Am. 1997;  79(3) 326-333
• 10 Carswell C I, Plosker G L. Bivalirudin: a review of its potential place in the management of acute coronary syndromes.  Drugs. 2002;  62(5) 841-870
• 11 Caron M F, McKendall G R. Bivalirudin in percutaneous coronary intervention.  Am J Health Syst Pharm. 2003;  60(18) 1841-1849
• 12 Ahrens I, Smith B K, Bode C, Peter K. Direct thrombin inhibition with bivalirudin as an antithrombotic strategy in general and interventional cardiology.  Expert Opin Drug Metab Toxicol. 2007;  3(4) 609-620
• 13 Dyke C M, Aldea G, Koster A et al.. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four heparin antibodies.  Ann Thorac Surg. 2007;  84(3) 836-839
• 14 Lewis B E, Walenga J M, Hursting M J. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia.  Cardiovascular Reviews of Reports. 2002;  23 445-457
• 15 Lewis B E, Matthai Jr W H, Cohen M et al.. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia.  Catheter Cardiovasc Interv. 2002;  57 177-184
• 16 Walenga J M, Ahmad S, Hoppensteadt D, Iqbal O, Hursting M J, Lewis B E. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia.  Thromb Res. 2002;  105(5) 401-405
• 17 Callas D, Fareed J. Comparative pharmacology of site directed antithrombin agents. Implication in drug development.  Thromb Haemost. 1995;  74(1) 473-481
• 18 Fareed J, Jeske W P, Hoppensteadt D A, Walenga J M. Update on the clinical applications of argatroban.  Future Cardiol. 2006;  2(4) 403-414
• 19 Walenga J M, Jeske W P, Prechel M M, Bakhos M. Newer insights on the mechanism of heparin-induced thrombocytopenia.  Semin Thromb Hemost. 2004;  30(suppl 1) 57-67
• 20 Walenga J M, Fareed D, Schultz C, Neville B, Hoppensteadt D. Argatroban, not lepirudin or bivalirudin, treatment results in the generation of nitric oxide during parenteral administration.  Blood. 2004;  104(11) 512a , (abstract)
• 21 Fareed J, Wahi R, Hoppensteadt D, Bansal V, Walenga J M, Kaiser B, Bick R. Anti-inflammatory effects of argatroban can be differentiated from other direct thrombin inhibitors. Experimental and clinical observations.  J Thromb Haemost. 2007;  5(suppl 2) , P-M-661 [abstract]
• 22 Loria V, Dato I, Graziani F, Biasucci L M. Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes.  Mediators Inflamm. 2008;  2008 135625
• 23 Heeschen C, Dimmeler S, Hamm C W et al.. Soluble CD40 ligand in acute coronary syndromes.  N Engl J Med. 2003;  348(12) 1104-1111
• 24 Klabunde R. Nitric oxide. Cardiovascular physiology concepts. 2008. Available at: http://www.cvphysiology.com/Blood%20Flow/BF011.htm Accessed March 26, 2008
• 25 Diamant M, Tushuizen M E, Sturk A, Nieuwland R. Cellular microparticles: new players in the field of vascular disease?.  Eur J Clin Invest. 2004;  34(6) 392-401